Literature DB >> 1718747

Tumor secretion of growth factors.

W H Daughaday1, T F Deuel.   

Abstract

An increasing number of polypeptide growth factors have been identified that regulate not only cell proliferation but also an extraordinary range of cell activities, including matrix protein deposition and resolution, the maintenance of cell viability, cell differentiation, inflammation, and tissue repair. Normal cells appear to require growth factors for proliferation and for maintenance of viability. Cells that secrete a polypeptide growth factor have an advantage in growth. These factors can act either externally through cell surface receptors or internally during the transport of receptors and growth factors through the endoplasmic reticulum and Golgi apparatus, causing autocrine stimulation of cell growth. Depending on the cell type, growth factors can also be potent inhibitors of cell growth rather than stimulators of growth, and the effect can depend on the presence or absence of growth factors. Among the growth factors considered, IGFs are unusual in that they function both as endocrine and as autocrine/paracrine agents. IGF-II, which is associated with fetal growth, is the IGF most frequently expressed by tumors. There is now convincing evidence that some tumors secrete sufficient IGF-II to have systemic endocrine effects as recognized as nonislet cell tumor hypoglycemia. PDGF is normally highly concentrated in platelets and has major significance in stimulation of cellular proliferation in inflammation and wound repair. Normally, this proliferation is self-limited, but the secretion of PDGF by tumors and its effects on cell proliferation of tumors persist. The fact that PDGF B monomer has an identical structure with that of the proto-oncogene C-cis further strengthens the connection between PDGF and tumor growth. EGF has a restricted role in normal physiology, but its close relative, TGF-alpha, is widely distributed in normal and neoplastic tissues. The common receptor for EGF and TGF-alpha is present in many normal and neoplastic cell types. The EGF receptor is the product of the C-erb gene. The oncogene V-cis is a truncated form of the EGF receptor whose tyrosine kinase activity is not dependent on ligand binding. TGF-beta exists in multiple forms. Although it can transform the morphology of certain cell lines in culture, it probably does not act generally as a mitogenic agent. Its major physiologic role in the body appears to be the stimulation of mesenchymal matrix formation. It is of special importance in the regulation of bone matrix formation. Its expression is increased in many tumors.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718747

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  12 in total

1.  Enzymatic cleavage of myoferlin releases a dual C2-domain module linked to ERK signalling.

Authors:  Ann-Katrin Piper; Samuel E Ross; Gregory M Redpath; Frances A Lemckert; Natalie Woolger; Adam Bournazos; Peter A Greer; Roger B Sutton; Sandra T Cooper
Journal:  Cell Signal       Date:  2017-02-10       Impact factor: 4.315

2.  Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia.

Authors:  K L Mohnike; U Kluba; U Mittler; V Aumann; P Vorwerk; W F Blum
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

3.  A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.

Authors:  M Nakamura; M Katano; K Fujimoto; T Morisaki
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

4.  Gangliosides inhibit PDGF-induced signal transduction events in U-1242 MG human glioma cells.

Authors:  H E Saqr; J D Walters; Z Guan; B T Stokes; A J Yates
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

5.  Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors.

Authors:  Carolina Torronteguy; Antonio Frasson; Felipe Zerwes; Erik Winnikov; Vinicius Duval da Silva; Antoine Ménoret; Cristina Bonorino
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

6.  Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.

Authors:  W H Daughaday; B Trivedi; R C Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 7.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

8.  A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.

Authors:  Victor M Santana; Natasha Sahr; Ruth G Tatevossian; Sujuan Jia; Olivia Campagne; April Sykes; Clinton F Stewart; Wayne L Furman; Lisa M McGregor
Journal:  Cancer       Date:  2020-01-22       Impact factor: 6.860

Review 9.  Does autocrine growth factor secretion form part of a mechanism which paradoxically protects against tumour development?

Authors:  T Dawson; D Wynford-Thomas
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone.

Authors:  H Wex; P Vorwerk; K Mohnike; D Bretschneider; U Kluba; V Aumann; W F Blum; U Mittler
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.